Campistol, Josep M.

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 3,047

In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration

Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 1,150

In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming.

Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., Li, M., Lam, D., Kurita, M., Beyret, E., et al. (2016) · Cell

Pluripotent Stem Cells ResearchGenetics, Aging, and Longevity in Model Organisms

Cited by 988

In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation

Liao, H.-K., Hatanaka, F., Araoka, T., Reddy, P., Wu, M.-Z., Sui, Y., Yamauchi, T., Sakurai, M., O’Keefe, D. D., Núñez-Delicado, E., et al. (2017) · Cell

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 451

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 321

Identification of Novel Long Noncoding RNAs Underlying Vertebrate Cardiovascular Development

Kurian, L., Aguirre, A., Sancho-Martinez, I., Benner, C., Hishida, T., Nguyen, T. B., Reddy, P., Nivet, E., Krause, M. N., Nelles, D. A., et al. (2015) · Circulation

Cancer-related molecular mechanisms researchCongenital heart defects research

Cited by 189

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)

Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., et al. (2011) · Transplantation

Renal Transplantation Outcomes and TreatmentsTransplantation: Methods and Outcomes

Cited by 183

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., et al. (2021) · The Lancet Neurology

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 158

Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation

Ramos-Cebrián, M., Torregrosa, J.-V., Gutiérrez-Dalmau, A., Oppenheimer, F., & Campistol, J.-M. (2007) · Transplantation Proceedings

Renal Transplantation Outcomes and TreatmentsTransplantation: Methods and Outcomes

Cited by 26

Isolation of Extracellular Vesicles Derived from Mesenchymal Stromal Cells by Ultracentrifugation

Ramirez-Bajo, M., Banon-Maneus, E., Rovira, J., Campistol, J. M., & Diekmann, F. (2020) · BIO-PROTOCOL

Extracellular vesicles in diseaseMesenchymal stem cell research

Cited by 10